Investigational drug · Phase 2
LY2784544
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neoplasms, Hematologic.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "LY2784544"
First trial start
2012
May 22, 2012
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY2784544", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasms, Hematologic
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LY2784544" as an intervention, largest first.
- A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT01594723 · 110 participants (planned) · Start May 22, 2012 · Primary completion Mar 20, 2015
Drug: 120 mg LY2784544 · For: Neoplasms, Hematologic
Sites: Rogers, Arkansas; Burbank, California; Norwalk, Connecticut · 39 sites in all
- Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01520220 · 100 participants · Start Jun 11, 2012 · Primary completion Jun 26, 2015
Drug: LY2784544 · For: Myeloproliferative Neoplasms of; Polycythemia Vera; Essential Thrombocythemia and 1 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Fayetteville, Arkansas · 9 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT01134120 · 80 participants (planned) · Start Apr 2010 · Primary completion Apr 2014
Drug: LY2784544 · For: Myeloproliferative Disorders; Thrombocythemia, Essential; Polycythemia Vera and 1 more
Sites: Houston, Texas; Salt Lake City, Utah
Newest research
PubMed records naming it or its code names, newest first.
- TIMP-2 Modulates 5-Fu Resistance in Colorectal Cancer Through Regulating JAK-STAT Signalling Pathway.
Xu C, Zhu R, Dai Q, et al. · J Cell Mol Med 2025
- Kv1.3 mediates ox-LDL-induced vascular smooth muscle cell proliferation through JAK2/STAT3 signaling pathway.
Liu L, Xu W, Li K, et al. · Arch Biochem Biophys 2023
- Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis.
Xu H, Liu Z, Weng S, et al. · Mol Oncol 2022
- JAK2 inhibition in JAK2V617F-bearing leukemia cells enriches CD34+ leukemic stem cells that are abolished by the telomerase inhibitor GRN163L.
Dahlström J, Xia C, Xing X, et al. · Biochem Biophys Res Commun 2020
- Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Berdeja J, Palandri F, Baer MR, et al. · Leuk Res 2018
- Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
Zhou W, Sun W, Yung MMH, et al. · Oncogene 2018
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.